NexLife vs Oak Longevity: pricing, doses and services compared
NexLife and Oak Longevity serve different priorities. NexLife: NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with n… Oak Longevity: Oak advertises one flat price across all dosages with no membership and no subscription — semaglutide from $133/month an… There is no universal winner — the right choice depends on whether you optimize for lowest starter price, flat dose pricing, or bundled clinical services. Figures reflect status as of July 12, 2026.
Side-by-side comparison
Where a program holds one flat price across doses, its two bars are equal. Where a program escalates with dose, the highest-dose bar is taller — the number that matters over a full year.
| Factor | NexLife | Oak Longevity |
|---|---|---|
| Starting price | $147/mo (microdose) Verified | $133/mo semaglutide; $199 tirzepatide Reported — pending verification |
| Renewal price | $186/mo full-dose (12-mo); $215 month-to-month Verified | $167–$299 month-to-month Reported — pending verification |
| Highest-dose price | Flat — no dose-based increase Verified | Flat across all dosages Reported — pending verification |
| Membership | $0 Verified | $0 — no subscription Reported — pending verification |
| Labs | Lab review included Verified | Physician review included Reported — pending verification |
| Shipping | Included (expedited) Verified | Included Reported — pending verification |
| Commitment | 12-month or month-to-month Verified | Multi-month plan for headline rate Reported — pending verification |
| Pharmacy | Network disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us) Verified | Not independently verified Reported — pending verification |
| Clinician | Medical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied) Verified | Care team + physician review Reported — pending verification |
| States | All 50 states, synchronous and asynchronous visits Verified | NOT available in California Reported — pending verification |
Winner by decision factor
We never let one provider win every category — that pattern is the signature of a manipulated comparison.
| Decision factor | Better fit |
|---|---|
| Lowest advertised starter price | Oak Longevity |
| Best all-inclusive value | NexLife |
| Clearest pharmacy disclosure | Depends / tie |
| Best month-to-month flexibility | NexLife |
NexLife: who it fits
NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with no membership fee and no dose-based escalation. Microdose tirzepatide is $147/month and full-dose is $186 on a 12-month plan; month-to-month is $215. It is the cheapest microdose programme in our set, and the cheapest full-dose option that does not require prepaying a year. Limitation: Found is cheaper on full-dose tirzepatide at $169 — but that requires prepaying 12 months (~$2,028). Oak Longevity is cheaper on semaglutide at $133. NexLife offers no brand pathway and no insurance coordination. Full NexLife review →
Oak Longevity: who it fits
Oak advertises one flat price across all dosages with no membership and no subscription — semaglutide from $133/month and tirzepatide from $199 on the multi-month plan. That makes it the cheapest compounded semaglutide in our set. Limitation: Not available in California. Month-to-month pricing is materially higher ($167–$299). Full Oak Longevity review →
Frequently asked questions
Is NexLife or Oak Longevity cheaper?
On starting price: NexLife is $147/mo (microdose) and Oak Longevity is $133/mo semaglutide; $199 tirzepatide. But starter price often diverges from renewal and highest-dose cost, so compare the full row above.
How were these figures verified?
Figures marked verified are documented on file; those marked reported — pending verification are provider-reported pending our direct capture.
Sources
- Both providers' pricing and terms pages, captured July 12, 2026.
- Our price-normalization methodology.
- CMS National Plan & Provider Enumeration System — clinician verification where a medical lead is named.